000130741 001__ 130741
000130741 005__ 20240131210810.0
000130741 0247_ $$2doi$$a10.1111/all.13099
000130741 0248_ $$2sideral$$a98985
000130741 037__ $$aART-2017-98985
000130741 041__ $$aeng
000130741 100__ $$0(orcid)0000-0001-8959-6784$$aColás, C.$$uUniversidad de Zaragoza
000130741 245__ $$aEstimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study
000130741 260__ $$c2017
000130741 5060_ $$aAccess copy available to the general public$$fUnrestricted
000130741 5203_ $$aBackground: Despite the socioeconomic importance of allergic rhinitis (AR), very few prospective studies have been performed under conditions of clinical practice and with a sufficiently long observation period outside the clinical trial scenario. We prospectively estimated the direct and indirect costs of AR in patients attending specialized clinics in Spain. Methods: Patients were recruited at random from allergy outpatient clinics in 101 health centers throughout Spain over 12 months. We performed a multicenter, observational, prospective study under conditions of clinical practice. We analyzed direct costs from a funder perspective (healthcare costs) and from a societal perspective (healthcare and non–healthcare costs). Indirect costs (absenteeism and presenteeism [productivity lost in the workplace]) were also calculated. The cost of treating conjunctivitis was evaluated alongside that of AR. Results: The total mean cost of AR per patient-year (n = 498) was €2326.70 (direct, €553.80; indirect, €1772.90). Direct costs were significantly higher in women (€600.34 vs €484.46, P = 0.02). Total costs for intermittent AR were significantly lower than for persistent AR (€1484.98 vs €2655.86, P < 0.001). Total indirect costs reached €1772.90 (presenteeism, €1682.71; absenteeism, €90.19). The direct costs of AR in patients with intermittent asthma (€507.35) were lower than in patients with mild-persistent asthma (€719.07) and moderate-persistent asthma (€798.71) (P = 0.006). Conclusions: The total cost of AR for society is considerable. Greater frequency of symptoms and more severe AR are associated with higher costs. Indirect costs are almost threefold direct costs, especially in presenteeism. A reduction in presenteeism would generate considerable savings for society.
000130741 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130741 590__ $$a6.048$$b2017
000130741 591__ $$aIMMUNOLOGY$$b25 / 155 = 0.161$$c2017$$dQ1$$eT1
000130741 591__ $$aALLERGY$$b4 / 27 = 0.148$$c2017$$dQ1$$eT1
000130741 592__ $$a2.702$$b2017
000130741 593__ $$aImmunology and Allergy$$c2017$$dQ1
000130741 593__ $$aImmunology$$c2017$$dQ1
000130741 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000130741 700__ $$aBrosa, M.
000130741 700__ $$aAntón, E.
000130741 700__ $$aMontoro, J.
000130741 700__ $$aNavarro, A.
000130741 700__ $$aDordal, M.T.
000130741 700__ $$aDávila, I.
000130741 700__ $$aFernández-Parra, B.
000130741 700__ $$aIbáñez, M.D.P.
000130741 700__ $$aLluch-Bernal, M.
000130741 700__ $$aMatheu, V.
000130741 700__ $$aRondón, C.
000130741 700__ $$aSánchez, M.C.
000130741 700__ $$aValero, A.
000130741 700__ $$aRhinoconjunctivitis, Committee, of, the, Spanish, Society, of, Allergy, and, Clinical, Immunology
000130741 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000130741 773__ $$g72, 6 (2017), 959-966$$pAllergy$$tAllergy: European Journal of Allergy and Clinical Immunology$$x0105-4538
000130741 8564_ $$s179460$$uhttps://zaguan.unizar.es/record/130741/files/texto_completo.pdf$$yPostprint
000130741 8564_ $$s1718148$$uhttps://zaguan.unizar.es/record/130741/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000130741 909CO $$ooai:zaguan.unizar.es:130741$$particulos$$pdriver
000130741 951__ $$a2024-01-31-19:17:24
000130741 980__ $$aARTICLE